Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CorMedix (CRMD) EPS (Basic) (2016 - 2025)

CorMedix (CRMD) has disclosed EPS (Basic) for 14 consecutive years, with $0.13 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) fell 45.83% to $0.13 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.16 through Dec 2025, up 796.77% year-over-year, with the annual reading at $2.25 for FY2025, 850.0% up from the prior year.
  • EPS (Basic) hit $0.13 in Q4 2025 for CorMedix, down from $1.42 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $1.42 in Q3 2025 to a low of -$0.25 in Q2 2023.
  • Historically, EPS (Basic) has averaged -$0.02 across 5 years, with a median of -$0.18 in 2022.
  • Biggest five-year swings in EPS (Basic): crashed 58.33% in 2022 and later surged 2940.0% in 2025.
  • Year by year, EPS (Basic) stood at -$0.21 in 2021, then rose by 4.76% to -$0.2 in 2022, then rose by 15.0% to -$0.17 in 2023, then soared by 241.18% to $0.24 in 2024, then tumbled by 45.83% to $0.13 in 2025.
  • Business Quant data shows EPS (Basic) for CRMD at $0.13 in Q4 2025, $1.42 in Q3 2025, and $0.29 in Q2 2025.